Grant ID RP240054
Awarded On February 21, 2024
Title Myeloid support of refractory and aggressive T-ALL at distinct tumor sites
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization The University of Texas at Austin
Principal Investigator/Program Director Lauren Ehrlich
Cancer Sites Childhood and Adolescent, Leukemia
Contracted Amount $1,400,000
Lay Summary

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, with the T-cell subtype, T-ALL, representing ~15% of cases. Although aggressive chemotherapy regimens have improved 5-year survival rates to over 90%, these therapies often result in lifelong morbidities. Also, patients who fail to respond to chemotherapy or who relapse have dismal outcomes. Therefore, there is an unmet clinical need to develop alternative therapies for T-ALL. Despite harboring leukemia-promoting mutations, T-ALL cells do not survive alone, but require signals from the tumor microenvironment (TME) to thrive. We found that myeloid cells from multiple leukemic organs support growth of mouse and human T-ALL...

Read More